Related Experiment Video
Updated: Apr 24, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
Pharmacotherapy for treatment of retinal vein occlusion
Valentina Sarao1, Federica Bertoli, Daniele Veritti
1University of Udine, Department of Ophthalmology , Piazza Santa Maria della Misericordia, 33100 Udine , Italy +39 0432559907 ; +39 0432559904 ; paolo.lanzetta@uniud.it.
Introduction:
Retinal vein occlusion (RVO) is a common vascular condition, which may cause blindness and impaired vision as a result of the development of macular oedema. The management of macular oedema due to RVO is complex and a multidisciplinary approach is required in order to limit disease progression and achieve a better clinical outcome.
Areas Covered:
An update and a brief review on the current treatment strategies were provided in patients with macular oedema following RVOs. Evidence available from prospective, multicentre clinical studies evaluating the use of VEGF inhibitors and steroids and from a selective literature search is reported.
Expert Opinion:
For many years, laser photocoagulation has been considered the standard of care for the treatment of branch RVO. However, new treatment modalities have been evaluated through randomised controlled trials. Recently, anti-VEGF agents and corticosteroids have been shown to be efficacious options in the treatment of RVO.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Venous Thrombosis III: Interprofessional Care
Angle Closure Glaucoma: Treatment
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Ophthalmic Drug Delivery Systems
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

